Related Experiment Video
Updated: Jul 19, 2026
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Anticoagulation in interventional cardiology: optimizing patient outcome
1Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik I, Universitätsklinikum Charité der Humboldt-Universitát zu Berlin, Germany.
Insights
Preventing blood clots after coronary angioplasty is key. Glycoprotein IIb/IIIa inhibitors, particularly abciximab, show promise in reducing thrombotic complications and late restenosis following percutaneous transluminal coronary angioplasty (PTCA).
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Thrombotic complications, including abrupt vessel closure and late restenosis, frequently occur after percutaneous transluminal coronary angioplasty (PTCA).
- Current strategies involve pre-treatment with heparin and aspirin, but optimal regimens remain undefined.
- Alternative anticoagulants like low-molecular-weight heparins and direct thrombin inhibitors lack demonstrated outcome benefits over standard heparin.
Purpose of the Study:
- To evaluate the efficacy of various antithrombotic agents in preventing complications following PTCA.
- To assess the impact of different anticoagulants and antiplatelet agents on acute and late thrombotic events.
- To identify agents that improve long-term outcomes and reduce restenosis rates.
Main Methods:
- Review of clinical trials investigating antithrombotic therapies in the context of PTCA.
- Comparative analysis of heparin, low-molecular-weight heparins, direct thrombin inhibitors, thrombolytic agents, and glycoprotein IIb/IIIa inhibitors.
- Examination of data on short-term (30-day) and long-term outcomes, including restenosis.
Main Results:
- Heparin and aspirin pre-treatment reduce thrombosis, but optimal use is not established.
- Continued heparin post-PTCA offers no benefit without angiographic thrombosis.
- Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) combined with aspirin and heparin show positive results.
- Abciximab demonstrated significantly improved 30-day outcomes and reduced late restenosis.
Conclusions:
- Glycoprotein IIb/IIIa inhibitors represent a significant advancement in managing PTCA-related thrombosis.
- Abciximab is particularly effective, showing benefits in both acute outcomes and late restenosis prevention.
- Further research may refine the use of other antithrombotic agents, but current evidence favors glycoprotein IIb/IIIa inhibitors for comprehensive risk reduction.
Abstract:
Thrombotic complications are a common sequel to percutaneous transluminal coronary angioplasty (PTCA), and may present either acutely as abrupt vessel closure, or as late restenosis. Pre-treatment with heparin, in conjunction with aspirin, reduces the incidence of thrombosis although the optimal dose and duration of treatment has still not been established. Continued heparin treatment after PTCA does not reduce the event rate in patients with no angiographic evidence of thrombosis. Low-molecular-weight heparins are more convenient to use than standard heparin and offer theoretical advantages, but these have not yet been demonstrated to affect outcomes. Similarly, there is no evidence that direct thrombin inhibitors improve long-term outcomes, despite their theoretical advantages over heparin. Mixed results have been seen with thrombolytic agents in abrupt vessel closure, but in unstable angina there is conclusive evidence that they are associated with a worse prognosis. Good results have been seen with the glycoprotein IIb/IIIa inhibitors, used in conjunction with aspirin and heparin. Trials of abciximab have shown significantly improved outcomes at 30 days, and encouraging trends have been seen with eptifibatide and tirofiban. Abciximab is the only agent in this class which has been demonstrated to reduce the incidence of late restenosis.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Cardiac Catheterization IV: Nursing Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care